Getinge AB (publ) (OTCMKTS:GNGBY - Get Free Report)'s stock price passed above its 50 day moving average during trading on Thursday . The stock has a 50 day moving average of $19.69 and traded as high as $21.90. Getinge AB (publ) shares last traded at $21.90, with a volume of 1,676 shares traded.
Getinge AB (publ) Stock Up 1.5 %
The company has a debt-to-equity ratio of 0.06, a current ratio of 0.78 and a quick ratio of 0.50. The stock has a market capitalization of $6.00 billion, a price-to-earnings ratio of 38.67 and a beta of 0.81. The firm's fifty day moving average is $19.79 and its 200-day moving average is $18.70.
Getinge AB (publ) (OTCMKTS:GNGBY - Get Free Report) last issued its earnings results on Tuesday, January 28th. The company reported $0.49 earnings per share (EPS) for the quarter. Getinge AB (publ) had a net margin of 4.71% and a return on equity of 9.84%.
About Getinge AB (publ)
(
Get Free Report)
Getinge AB (publ) provides products and solutions for operating rooms, intensive-care units, and sterilization departments. The company operates through Acute Care Therapies, Life Science, and Surgical Workflows segments. It offers extracorporeal membrane oxygenation, mechanical ventilation, mechanical circulatory support, advanced patient monitoring, ICU infrastructure equipment, patient flow management, and drainage solutions.
Featured Stories
Before you consider Getinge AB (publ), you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Getinge AB (publ) wasn't on the list.
While Getinge AB (publ) currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Unlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.